Anti-Diabetic and Anti-Obesity Therapeutic
- Technology Benefits
- Reduces adiposity without elevating plasma triglyceride levelsImproves glucose homeostasis by several potential mechanisms and directly targets both white and brown adipose tissue
- Technology Application
- Anti-diabetic, anti-obesity therapeuticComposition for improving insulin sensitivity of obese and diabetic patients
- Detailed Technology Description
- None
- Application No.
- WO2016086155
- Others
-
Tech ID/UC Case
24275/2015-010-0
Related Cases
2015-010-0
- *Abstract
-
Obesity and its associated metabolic diseases, including type 2 diabetes, are components of a global epidemic. However, the pharmacological approaches against obesity and metabolic diseases are limited. Research is growing on a secreted protein, Angiopoietin-like 4 (ANGPTL4), that inhibits lipoprotein lipase (LPL) activity and promotes lipolysis in adipocytes.
A UC Berkeley researcher is currently examining the role of ANGPTL4 and variants thereof, particularly the C-terminal fibrinogen-like domain (FLD) of ANGPTL4. Using animal models, the UC researcher found that increasing plasma FLD levels protected the animal from diet-induced obesity without affecting plasma triglyceride levels and improve glucose homeostasis. The discovery targets both white and brown adipose tissue, thus it provides a different approach to reduce obesity, complementing current pharmacological therapies. In addition, the discovery provides compositions and methods to improve insulin sensitivity in type 2 diabetes patients.
- *IP Issue Date
- Jun 2, 2016
- *Principal Investigator
-
Name: Jen-Chywan Wang
Department:
- Country/Region
- USA
